Device Trial Radar · NCT07912541
ADVA ACE Coronary Stent System in Coronary Artery Disease Patients (ADVANCE)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2028
Study completion May 2029
Sponsor
- Lead sponsor
- Advanced MedTech Solutions Pvt. Ltd.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Clicebo Solutions Private Limited
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, global, multi-centre, single-arm clinical study to evaluate the Safety and Performance of ADVA ACE Everolimus eluting Coronary Stent System in Coronary Artery Disease in Indian \& European population. To evaluate the performance of ADVA ACE Everolimus Eluting Stent, follow up indicated by MACE at 6 months. Of the 110, 40 patients will be assigned to European population, and 70 patients will be assigned to Indian population. QCA is applicable to all Indian patients while OCT applicable for 10 Indian patients only at baseline and 6-months follow-up visit. A QCA Analysis will be performed on all 70 patients in Indian population \& 10 Indian patients only. Interval (Days) for patients visit at Day 0, Day 30±14, Day 180±14 and Day 360±14.
Conditions
- Coronary Artery Disease
- De Novo Stenosis Lesion
- Coronary Stent Implantation
Interventions
ADVA ACE Everolimus Eluting Coronary Stent SystemDevice
ADVA ACE - Everolimus Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (coronary stent system) and a drug product (a formulation of Everolimus contained in a biodegradable polymer coating). is uniquely designed with a low polymer load, abluminal coating and bioabsorbable polymer matrix which may reduce the risk of thrombosis and the need for prolonged dual antiplatelet therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major adverse cardiac events (MACE) - defined as composite of cardiovascular death, non-fatal myocardial infarction (MI), and clinically driven target vessel revascularization (CD-TVR)Time frame: 180 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.